Please provide your email address to receive an email when new articles are posted on . Zimislecel is an investigational stem cell-derived islet therapy for type 1 diabetes. Ten of 12 participants no ...
PTCLs are a heterogeneous group of aggressive disorders representing 10–15% of non-Hodgkin lymphoma (NHL) and approximately 3% of all hematological malignancies 1,2. First-line treatment for the most ...
The alternative text for this image may have been generated using AI. Among the 37 infused patients, a median of 12 cell doses per participant (range 2–28) was produced and available for infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results